Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 June 2022.
During the last quarter, Patrys has made substantial progress in expanding the base of evidence to support the range of potential clinical applications for its deoxymabs.
Key achievements include:
- $250,000 non-dilutive funding to support research by the Telethon Kids’ Institute into potential therapeutic applications for Patrys’ deoxymabs;
- New research published showing potential to use PAT-DX1 to regulate Neutrophil Extracellular Traps that play a role in cancer metastasis and inflammation;
- Update on research collaboration with Imagion to develop new targeted antibody-based imaging agents for brain cancer;
Our Company holds a strong financial position, with a closing cash balance of $7.8M at 30 June 2022, with an additional $2M in short-term investments.